杂志简称：j atheroscler thromb
中文译名：《动脉硬化与血栓杂志》
收录属性：scie（2024版）, 目次收录（维普）,英文期刊,
自引率：12.20%
投稿方向：医学、peripheral vascular disease 外周血管病
SCI/E期刊基本信息
出版周期：月刊 地区：日本
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：OA期刊
国际标准刊号：ISSN1340-3478；EISSN1880-3873
杂志语言：英语
出版国家：日本
杂志官网 联系方式
出版地址：JAPAN ATHEROSCLEROSIS SOC,C/O KYOWA KIKAKU LTD,2-20-25,SHINBASHI,MINATO-KU,TOKYO,JAPAN,105-0004
杂志邮箱：
投稿网址：http://jat-submit.highwire.org/
杂志官方网址：https://www.jstage.jst.go.jp/browse/jat
出版商网址：http://www.j-athero.org/
杂志投稿要求
投稿须知【杂志社官方网站信息】
Instructions to Authors
Prior Publication:
The Journal of Atherosclerosis and Thrombosis, JAT, is the official publication of the Japan Atherosclerosis Society (JAS) and the Asian-Pacific Society of Atherosclerosis and Vascular Disease (APSAVD). Contribution from non-members is also acceptable.
JAT publishes articles focused on all aspects of research on atherosclerosis, vascular biology, thrombosis, lipid and metabolism.
The editors of JAT aim to publish original contributions. Therefore, for Original Article, Case Report, Editorial and Correspondence, JAT will not publish articles in which a significant portion of the data, either in the form of figures or tables, has been published or submitted for publication elsewhere. JAT requires the authors’ state in their cover letter that no data similar to those reported in their manuscript have been published elsewhere other than in abstract form and that they are not under consideration for publication elsewhere.
JAT will not tolerate misconduct including, but not limited to, data fabrication or falsification including deceptive manipulation of images and plagiarism. If any manuscript is found to contain misconduct, the review process will be halted immediately, and the University or Institute of the corresponding Author could be informed at the discretion of the editorial committee and the ethical committee of JAS.
COI: In accordance with the JAS Conflict of Interest Policy, the JAT requires all authors to disclose any financial relationship (within the past 36 months) with a biotechnology manufacturer, a pharmaceutical company or any other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. Upon submitting the manuscript, click a checkbox next to either YES or No. Prior to acceptance, the corresponding author is required to provide details regarding all authors’ financial interests if there is anything to disclose, and the editorial staff will verify all of the disclosures described in the article. If any inaccuracy is found in the information disclosed, the editorial office will decline to publish the manuscript, or if it is already published, then the editorial office will deal with the matter in accordance with the JAS Conflict of Interest Policy.
Copyright:
Each author must release first and subsidiary rights to their manuscript at the time of acceptance for publication by forwarding dated copyright form containing signature of the author.
JAT allows others to download the material and share it (either whole or parts of it) with others without any permission as long as they credit the original source and indicate if changes were made. But they can't use the material commercially. The original source should also be included in the reference list, if any.
Ethics:
When reporting experiments on human subjects, indicate whether the procedures followed were in accord with the ethical standards of the responsible institutional or regional committee on human experimentation or in accord with the latest the latest the latest the latest the latest the latest the latest the latest the latest the latest the latest version of DECLARATION OF HELSINKI. Do not use patient names or initials or hospital name in the manuscript. When reporting experiments on animals, indicate whether the institution’s guidelines for the care and use of laboratory animals were followed.Manuscripts should be submitted through online system by accessing http://jat-submit.highwire.org/ and other scientific correspondence should be addressed to:
JAT Editorial Office
Japan Atherosclerosis Society
Nichinai-Kaikan B1, 3-28-8 Hongo
Bunkyo-ku, Tokyo 113-0033, Japan
E-mail: jat-office@j-athero.or.jp